Successful completion of first phase in human clinical trial
28-05-2021 – Hylomorph has announced the positive evaluation by an independent Data Safety Monitoring Board of the clinical safety for their product Hylomate.
The ongoing clinical study, called the ‘Hylomate Trial’, is a multi-center, confirmatory, single-arm study, with endpoints of safety in combination with cardiac rhythm management devices (pacemakers and defibrillator indications) and performance related to the maintenance of stable interface with the surrounding soft tissues and minimization of fibrotic capsule.
